Phathom Pharmaceuticals, INC Form 4 insider transactions

Phathom Pharmaceuticals, Inc. Director Frank Karbe was granted 10,500 Restricted Stock Units and 17,500 stock options as part of the company's Non-Employee Director Compensation Program.

Phathom Pharmaceuticals, Inc. Director Michael F. Cola was granted 10,500 Restricted Stock Units and 17,500 stock options as part of the company's non-employee director compensation program.

James N. Topper, a Director and 10% owner of Phathom Pharmaceuticals, Inc., was granted 10,500 Restricted Stock Units and options to purchase 17,500 shares of common stock as part of his non-employee director compensation.

Phathom Pharmaceuticals, Inc. Director Heidi Fields was granted 10,500 Restricted Stock Units and 17,500 stock options as part of the company's Non-Employee Director Compensation Program.

Phathom Pharmaceuticals, Inc. Director Mark Stenhouse was granted 10,500 Restricted Stock Units and 17,500 stock options as part of the company's Non-Employee Director Compensation Program.

Phathom Pharmaceuticals, Inc. Director Asit Parikh was granted 10,500 Restricted Stock Units and 17,500 stock options as part of the company's Non-Employee Director Compensation Program.

Phathom Pharmaceuticals, Inc. Director and 10% Owner James N. Topper has acquired an additional 3,780 shares of common stock, signaling increased insider confidence.

Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals, reports the acquisition of stock options.

Director James N. Topper reports transactions in Phathom Pharmaceuticals stock, including purchases made indirectly through Frazier Life Sciences X, L.P. and other entities.

Director James N. Topper reports multiple purchases of Phathom Pharmaceuticals (PHAT) common stock through various entities.

Director Asit Parikh of Phathom Pharmaceuticals, Inc. reports purchasing 10,000 shares of common stock in two transactions.

Theodore R. Schroeder, a director at Phathom Pharmaceuticals, acquired 21,000 shares of common stock and options to purchase 35,000 shares on April 16, 2025.

Molly Henderson, CFO and CBO of Phathom Pharmaceuticals, sold 3,678 shares of common stock on April 7, 2025, to cover tax withholding obligations related to the settlement of restricted stock units.

Steven L. Basta, President and CEO of Phathom Pharmaceuticals, acquired 360,000 performance shares and 1,085,000 stock options on April 3, 2025.

Asit Parikh, a director at Phathom Pharmaceuticals, exercised stock options on September 10, 2024, acquiring 7,500 shares of common stock.

Director Asit Parikh of Phathom Pharmaceuticals, Inc. (PHAT) acquired 10,000 shares of common stock at an average price of $4.42 on March 13, 2025, increasing his total holdings to 85,500 shares.

Phathom Pharmaceuticals' CEO, Terrie Curran, was granted stock options to purchase 342,500 shares of common stock on February 27, 2025, according to a Form 4 filing.

Molly Henderson, CFO and CBO of Phathom Pharmaceuticals, reports the acquisition of 72,000 shares of common stock and 50,000 stock options.

Azmi Nabulsi, Chief Operating Officer of Phathom Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Molly Henderson, CFO and CBO of Phathom Pharmaceuticals, sold 6,583 shares of common stock on January 21, 2025, to cover tax withholding obligations.

Azmi Nabulsi, Chief Operating Officer of Phathom Pharmaceuticals, sold shares to cover tax withholding obligations upon the settlement of restricted stock units.

Phathom Pharmaceuticals' CEO, Terrie Curran, sold 19,109 shares of common stock on January 21, 2025, to satisfy tax withholding obligations related to the settlement of restricted stock units.

Azmi Nabulsi, Chief Operating Officer of Phathom Pharmaceuticals, sold 1,118 shares of common stock to cover tax obligations related to the settlement of restricted stock units.

Molly Henderson, CFO and CBO of Phathom Pharmaceuticals, sold 1,291 shares of common stock on December 19, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Director Frank Karbe of Phathom Pharmaceuticals purchased 12,500 shares of common stock at a weighted average price of $7.9267 on December 13, 2024.

Director Asit Parikh of Phathom Pharmaceuticals purchased 10,000 shares of common stock at a weighted average price of $8.1248 on December 13, 2024.

Azmi Nabulsi, Chief Operating Officer of Phathom Pharmaceuticals, sold 10,901 shares of common stock on July 15, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Molly Henderson, CFO and CBO of Phathom Pharmaceuticals, reports selling shares to cover tax obligations and acquiring shares through the employee stock purchase plan.

Phathom Pharmaceuticals CEO Terrie Curran sold shares to cover tax obligations and acquired shares through the employee stock purchase plan.

Molly Henderson, CFO and CBO of Phathom Pharmaceuticals, reports the acquisition of 7,500 shares of common stock and ownership of 102,763 shares.